SPIROMICS队列中COPD低血嗜酸性粒细胞计数的临床意义
基于SPIROMICS COPD队列(n=1,414)及GOLD D组(n=185)未用ICS者,比较血嗜酸性粒细胞≤100 vs >100 cells/μL的基线与纵向结局。全队列两组肺功能下降、急性加重、ICS启用及死亡率相似;但GOLD D组中BEC≤100者急性加重率更高、肺功能下降更快、基线肺气肿更多。
要点
- GOLD D组未用ICS者BEC≤100与更高的急性加重率相关。
- GOLD D组BEC≤100者肺功能下降更快且基线肺气肿更多。
- 全队列中BEC≤100与BEC100+的纵向结局无显著差异。
核心结论
- 在未用ICS的GOLD D组COPD患者中,BEC≤100者基线肺气肿更多、前瞻性急性加重更多、肺功能下降更快。
- 分析识别出COPD中尤其脆弱的亚群,提示需针对其治疗开展专门研究。
研究设计与样本
- 使用多变量混合模型和逻辑回归,对比所有COPD受试者(n=1,414)及GOLD D组(n=185)未用ICS者中BEC≤100与BEC>100的临床特征和结局。
- BEC≤100共485例(其中GOLD D组61例),BEC100+共929例(其中GOLD D组124例)。
主要发现
- BEC≤100状态在6周和约52周稳定,组内相关系数分别为0.78和0.71。
- 与BEC100+相比,BEC≤100者女性更多、当前吸烟更多、儿童期哮喘更少。
关键数值与推荐
- GOLD考虑血嗜酸性粒细胞计数<100 cells/μL(BEC≤100)的COPD患者预测ICS反应差。
- BEC≤100状态在6周和约52周稳定(组内相关系数0.78和0.71)。
临床怎么用
- 对未用ICS的GOLD D组COPD患者,BEC≤100提示急性加重和肺功能下降风险更高,应加强监测。
- BEC≤100的GOLD D组患者基线肺气肿更多,临床评估中需关注肺气肿表型。
- 全队列中BEC≤100与BEC100+结局相似,不宜仅凭BEC≤100在全部COPD中判断预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) considers blood eosinophil counts < 100 cells/μL (BEC≤100) in people with COPD to predict poor inhaled corticosteroid (ICS) responsiveness. However, the BEC≤100 phenotype is inadequately characterized, especially in advanced COPD. RESEARCH QUESTION: Are there differences between GOLD group D patients with high BEC and those with low BEC regarding baseline characteristics and longitudinal outcomes? STUDY DESIGN AND METHODS: We used multivariable mixed models and logistic regression to contrast clinical characteristics and outcomes of BEC≤100 vs BEC > 100 (BEC100+) in all subjects with COPD (n = 1,414) and GOLD group D subjects (n = 185) not receiving ICS. RESULTS: We identified n = 485 with BEC≤100 (n = 61 GOLD group D) and n = 929 people with BEC100+ (n = 124 GOLD group D). BEC≤100 status was stable at 6 weeks and approximately 52 weeks (intraclass correlations of 0.78 and 0.71, respectively). Compared with BEC100+, BEC≤100 comprised more women, with greater current smoking, and less frequent childhood asthma. Among all analyzed participants, the two BEC-defined subsets showed similar rates of lung function decline (mean slope, BEC≤100 vs BEC100+, -50 vs -39 mL/y; P = .140), exacerbations (0.40 vs 0.36/y; P = .098), subsequent ICS initiation (2.5% vs 4.4%; P = .071), and mortality (7.8% vs 8.4%; P = .715). However, in GOLD group D, people with BEC≤100 showed higher exacerbation rates within 365 days of enrollment (0.62 vs 0.33/y; P = .002) and total follow-up (1.16 vs 0.83/y; P = .014). They also had greater lung function decline (mean slope of -68 mL/y vs -23 mL/y; P = .036) and had greater emphysema at baseline (voxels < 950 Hounsfield units at total lung capacity of 7.46% vs 4.61%; P = .029). INTERPRETATION: In non-ICS-treated GOLD group D COPD, people with BEC≤100 had more baseline emphysema, prospective exacerbations, and lung function decline. Our analysis has identified a particularly vulnerable subpopulation of people with COPD, suggesting the need for studies focused specifically on their therapeutic treatment. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT01969344; URL: www. CLINICALTRIALS: gov.
引用
- LeMaster, Quibrera, Couper, et al. Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort. Chest. 2022. PMID: 36343688. doi:10.1016/j.chest.2022.10.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。